Intriguing results from Du et al. suggested that a low CDKN2B-AS1 expression in the peripheral blood of IPF patients may promote the occurrence of lung cancers by regulating the P53 signaling pathway [63]. This evidence concerns the gene CDKN2B and idiopathic pulmonary fibrosis.